2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.

[1]  J. Janc,et al.  Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets. , 2002, Chemistry & biology.

[2]  J. Janc,et al.  A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site. , 2002, Journal of molecular biology.

[3]  Erik Verner,et al.  Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator. , 2001, Journal of medicinal chemistry.

[4]  B. Katz,et al.  Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa. , 2001, Journal of medicinal chemistry.

[5]  N. Brünner,et al.  Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. , 2001, Cancer research.

[6]  B. Katz,et al.  Emerging therapeutic targets in oncology: urokinase-type plasminogen activator system , 1999 .

[7]  D. Gomez,et al.  Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428. , 1998, Anticancer research.

[8]  J. Tang,et al.  Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. , 1998, Science.

[9]  A. Mazar,et al.  Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. , 1997, Cancer research.

[10]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[11]  H. Bestmann,et al.  An Improved One-pot Procedure for the Synthesis of Alkynes from Aldehydes , 1996 .

[12]  A. Mazar,et al.  Prevention of prostate‐cancer metastasis in vivo by a novel synthetic inhibitor of urokinase‐type plasminogen activator (uPA) , 1995, International journal of cancer.

[13]  F. Jänicke,et al.  Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. , 1995, Journal of obstetrics and gynaecology.

[14]  L. Ossowski,et al.  Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. , 1991, Cancer research.

[15]  S. Ohira.  Methanolysis of Dimethyl (1-Diazo-2-oxopropyl) Phosphonate: Generation of Dimethyl (Diazomethyl) Phosphonate and Reaction with Carbonyl Compounds , 1989 .

[16]  L. Ossowski,et al.  Antibodies to plasminogen activator inhibit human tumor metastasis , 1983, Cell.